ImmunoPrecise Antibodies (NASDAQ:IPA) Issues Quarterly Earnings Results

ImmunoPrecise Antibodies (NASDAQ:IPA) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06), Zacks reports. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%.

ImmunoPrecise Antibodies Stock Down 5.7 %

IPA traded down $0.03 during trading on Friday, reaching $0.42. 179,288 shares of the stock traded hands, compared to its average volume of 2,065,203. The stock’s 50-day simple moving average is $0.44 and its two-hundred day simple moving average is $0.48. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. ImmunoPrecise Antibodies has a fifty-two week low of $0.27 and a fifty-two week high of $1.64. The stock has a market cap of $12.89 million, a price-to-earnings ratio of -0.53 and a beta of 0.09.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.